Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165503 | 0.85 | CTNNB1 (0.64) | CTNNB1L3MBTL1ALDH1A1HPGDGAA | |
| SCHEMBL12165496 | 0.83 | HPSE (0.52) | CTNNB1L3MBTL1ALDH1A1HPGDGAA | |
| SCHEMBL2705425 | 0.82 | RECQL (0.65) | RECQLLMNAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL9244913 | 0.82 | CTNNB1 (0.60) | CTNNB1L3MBTL1ALDH1A1HPGDGAA | |
| SCHEMBL466194 | 0.81 | CTNNB1 (0.71) | CTNNB1L3MBTL1ALDH1A1HPGDGAA | |
| SCHEMBL6957797 | 0.80 | PTGER1 (0.58) | RECQLCYP2C9HTTKMT2AKDM4E | |
| SCHEMBL9540049 | 0.79 | RECQL (0.79) | RECQLCYP3A4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12165506 | 0.79 | TSHR (0.52) | CYP1A2CYP2C9CYP2C19CYP3A4CTNNB1 | |
| SCHEMBL6059424 | 0.79 | NR4A1 (0.60) | CYP1A2CYP2C9CYP2C19CYP3A4CTNNB1 | |
| SCHEMBL12505440 | 0.79 | CTNNB1 (0.65) | CYP1A2CYP2C9CYP2C19CYP3A4CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493305-B1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| WO-2011053697-A1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORPORATION (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | RECQL 957/4885CYP1A2 28/4885CYP2C9 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.